Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025VaccineOpen Access

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKenji KuriyamaKMKyoko MurakamiKSKenkichi Sugiura

Discussion

Loading...

Member takes

Overview

Phase 3 trial showed robust immune responses from NVX-CoV2373 boosters, highlighting safety and effectiveness.

Key Points

  • The second booster dose induced durable anti-SARS-CoV-2 immune responses up to one year.
  • Immunogenicity peaked with IgG responses at D29 and neutralizing antibodies at D15 after both doses.
  • No deaths or severe adverse events occurred at the one-year follow-up for participants in both study parts.
  • About 14% of participants in the main part reported mild to moderate SARS-CoV-2 infections.

Cite This Study

Kuriyama et al. (2025) studied this question.

synapsesocial.com/papers/68c1b34654b1d3bfb60e9702https://doi.org/10.1016/j.vaccine.2025.127562
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial2025 · 2 citations
  2. 2Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine2024 · 8 citations
  3. 3Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study2026 · 1 citations
  4. 4Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants2023 · 34 citations
  5. 5A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses2023 · 4 citations